MIAMI (Nov. 22)—Cordis Corp., a Johnson & Johnson company, has received approval from the U.S. Food and Drug Administration to market the firm´s Checkmate System. The system is the first intravascular radiation unit available for blockage in coronary arteries previously treated with coronary artery stents, a Cordis spokeswoman said. Following placement of a coronary artery stent, the vessel wall can respond by forming scar tissue that pushes through the openings in the stent mesh, she said. The Checkmate system is intended to interrupt scar tissue growth in the vessel wall.
FDA OKs Cordis´ Checkmate System
Rubber & Plastics News wants to hear from its readers. If you want to express your opinion on a story or issue, email your letter to Editor Bruce Meyer at [email protected].